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Abstract
Background: Recent studies suggest that the pathogenic process in neurodegenerative disorders may disrupt
mature neuronal circuitries and neurogenesis in the adult brain. Abnormal activation of CDK5 is associated with
neurodegenerative disorders, and recently a critical role for CDK5 in adult neurogenesis has been identified. We
have developed an in vitro model of abnormal CDK5 activation during adult hippocampal neurogenesis, and here
we used this model to investigate aberrantly phosphorylated downstream targets of CDK5.
Results: Abnormal CDK5 activation in an in vitro model of adult neurogenesis results in hyperphosphorylation of
collapsin-response mediator protein-2 (CRMP2) and impaired neurite outgrowth. Inhibition of CDK5, or expression
of a non-phosphorylatable (S522A) CRMP2 construct reduced CRMP2 hyperphosphorylation, and reversed neurite
outgrowth deficits. CRMP2 plays a role in microtubule dynamics; therefore we examined the integrity of
microtubules in this model using biochemical and electron microscopy techniques. We found that microtubule
organization was disrupted under conditions of CDK5 activation. Finally, to study the relevance of these findings to
neurogenesis in neurodegenerative conditions associated with HIV infection, we performed immunochemical
analyses of the brains of patients with HIV and transgenic mice expressing HIV-gp120 protein. CDK5-mediated
CRMP2 phosphorylation was significantly increased in the hippocampus of patients with HIV encephalitis and in
gp120 transgenic mice, and this effect was rescued by genetic down-modulation of CDK5 in the mouse model.
Conclusions: These results reveal a functional mechanism involving microtubule destabilization through which
abnormal CDK5 activation and CRMP2 hyperphosphorylation might contribute to defective neurogenesis in
neurodegenerative disorders such as HIV encephalitis.
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Background
During aging and in the progression of neurodegenera-
tive conditions such as Alzheimer’s disease (AD) and
HIV-associated neurocognitive disorders, synaptic plasti-
city and neuronal integrity are disturbed [1-3]. Although
the precise mechanisms leading to neurodegeneration in
these conditions remain unclear, some common
signaling factors have been identified that contribute to
the pathogenesis of multiple neurodegenerative pro-
cesses. One important signaling molecule that may
represent a common denominator in several neurode-
generative disorders is cyclin-dependent kinase-5
(CDK5). Previous studies have revealed that dysregula-
tion of CDK5 and its activators p35 and p25 contribute
to the abnormal accumulation of hyperphosphorylated
CDK5 substrates and eventual mature neuronal cell
death in AD, HIV-associated neuroinflammatory condi-
tions such as HIV encephalitis (HIVE), and prion-related
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studies have shown that levels of CDK5 are increased in
the brains of AD [7] and HIVE [8] patients, and in scra-
pie-infected hamsters [6].
In addition to the alterations in synaptic plasticity in
mature neurons in these disorders, recent studies have
uncovered evidence suggesting that the pathogenic pro-
cess in humans and animal models of AD and HIV in
the brain might include dysregulation of adult neuro-
genesis [9-14]. This suggests that neurodegeneration
may be characterized by not only a loss of mature neu-
rons but also by a decrease in the generation of new
neurons in the neurogenic niches of the adult brain.
These cell populations that could be targeted include
neural progenitor cells (NPCs) in the subventricular
zone (SVZ) and in the dentate gyrus (DG) of the hippo-
campus. Mechanisms of neurogenesis in the fetal brain
have been extensively studied, however less is known
about the signaling pathways regulating neurogenesis in
the adult nervous system and their role in neurodegen-
erative disorders.
It is clear that the abnormal activation of CDK5 via
calpain-mediated cleavage of p35 into the more stable
p25 fragment contributes to the pathogenesis of neuro-
degenerative conditions such as AD and HIVE [4-6,8],
however, previous studies have also demonstrated that
physiological CDK5 activity is essential for adult neuro-
genesis [15,16]. Thus, it is possible that abnormal activa-
tion of CDK5 and aberrant phosphorylation of its
physiological substrates might have detrimental effects
on cells residing in the neurogenic niches of the adult
brain, and deficits in neurogenesis associated with neu-
rodegeneration might be related to alterations in CDK5
in NPCs. In support of this possibility, we have pre-
viously shown that abnormal CDK5 activation impairs
neurite outgrowth and neuronal maturation in an in
vitro model of adult neurogenesis, and in a mouse
model of AD-like neurodegeneration and impaired neu-
rogenesis [17]. However, the downstream regulators
mediating CDK5-associated defective neurogenesis are
unknown.
In this context, CDK5 may mediate alterations in neu-
rogenesis in AD and HIVE via aberrant phosphorylation
of its substrates, which include cytoskeletal (neurofila-
ments, nestin) [18] and synaptic proteins (e.g. synapsin)
[19], among others. It is possible that CDK5 substrates
implicated in toxicity to mature neuronal populations,
such as tau, might be involved, however another possibi-
lity is that alternative downstream substrates of CDK5
might modulate neurogenesis and neuronal maturation
in the adult hippocampus. Elucidating the signaling
pathways and downstream molecular targets involved in
the dysregulation of neurogenesis is important to fully
understand the mechanisms of neuroplasticity in neuro-
degenerative disorders.
A subset of physiological substrates of CDK5 includes
proteins that have been implicated in neurogenesis
(doublecortin, nestin) or neuronal development (collap-
sin-response mediator protein-2 [CRMP2]). Interest-
ingly, in previous reports, CDK5-mediated
phosphorylation of CRMP2 has been linked to neurode-
generation in AD [20-22], and the known role of this
protein in growth cone collapse and neuronal develop-
ment makes it an intriguing candidate for regulating
neurogenesis in neurodegenerative disorders. Notably,
several recent proteomics-based studies in the brains of
human HIV patients have detected differential expres-
sion of CRMP2 in human cases with HIVE or HIV-asso-
ciated dementia [23,24]. Since the role of CRMP2
phosphorylation has not been previously examined in
the adult neurogenic niche, or in HIV-associated neuro-
degenerative disorders (HAND), we sought to better
understand the potential function of this protein in the
molecular mechanisms involved in CDK5-mediated dys-
regulation of adult neurogenesis using an in vitro model
of CDK5 activation in adult hippocampal NPCs [17],
and in vivo in the brains of patients with HIV and in an
animal model of HIV protein neurotoxicity. Here we
demonstrate that aberrant phosphorylation of collapsin-
response mediator protein-2 (CRMP2) is a critical
downstream event contributing to impaired neurite out-
growth in an in vitro model of abnormal activation of
CDK5 in adult neurogenesis. Using biochemical techni-
ques with genetic and pharmacological manipulation of
the p35/CDK5/CRMP2 signaling pathway, we examined
the effects of abnormal activation of CDK5 on neurite
outgrowth and CRMP2 phosphorylation in NPC-derived
neural progeny. We further investigated the contribution
of CDK5-mediated hyperphosphorylation of CRMP2 in
neurodegenerative processes in vivo by evaluating
expression and phosphorylation of CRMP2 in the neu-
rogenic niche of human brains with HIVE and in gp120
transgenic (tg) mice. These results reveal a role for
CRMP2 in impaired neuronal maturation mediated by
abnormal CDK5 activation, and identify a potential
downstream functional mechanism involving microtu-
bule destabilization that could contribute to impaired
neuronal maturation during adult neurogenesis in neu-
rodegenerative conditions.
Results
CRMP2 phosphorylation is increased in an in vitro model
of adult neurogenesis with abnormal CDK5 activation
In order to investigate the molecular mechanisms that
might contribute to defective adult neurogenesis in neu-
rodegenerative disorders, we utilized a model system of
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induced by virus-mediated overexpression of the CDK5
activator, p35. We have previously shown that these
conditions result in dramatically reduced neurite out-
growth of b-Tubulin-positive processes compared to
vehicle-treated controls [17]. At high magnification, cells
expressing high levels of p35 had significantly shorter
processes and diffuse cytoplasmic b-Tubulin immunor-
eactivity compared to vehicle-treated controls (Figure
1A-C). This suggests that CDK5 plays a critical role dur-
ing neuronal maturation of adult hippocampal NPCs,
however the downstream mediators of this effect are
unknown. It is possible that CDK5 substrates implicated
in toxicity to mature neuronal populations, such as tau,
might be involved, however it is also possible that alter-
native targets of CDK5 might modulate neuronal
maturation in the adult hippocampus.
CRMP2 has been previously identified as a down-
stream target of CDK5 and is phosphorylated by this
kinase at the Ser522 epitope [25,26]. Although abnormal
CDK5 activation has been implicated in neurodegenera-
tion, and CDK5 is critical in the process of adult neuro-
genesis, the role of CRMP2 in neurogenesis under
conditions of abnormal CDK5 activation is unclear. In
Figure 1 Impaired neurite outgrowth is accompanied by CRMP2 hyperphosphorylation in NPC-derived neural progeny overexpressing
p35. Differentiating NPCs were grown on glass coverslips and infected on day 2 with an adenoviral vector expressing p35. Cells were processed
for immunocytochemistry and immunoblot analyses. For b-tubulin immunofluorescence, on day 4, cells were briefly extracted, then fixed with
glutaraldehyde and processed. (A,B) Reduced b-tubulin-immunoreactive neurites in NPC-derived neural progeny infected with p35-adv. (C)
Quantitative image analysis showing reduced neurite lengths in NPC-derived neural progeny with p35 expression. (D) Immunoblot analysis of
cell lysates from control and p35-expressing NPCs using a panel of antibodies specific for various isoforms and phosphorylated forms of CRMP.
(E) Immunoblot analysis of total cell lysates showing increased CRMP2 phosphorylation in NPC-derived neural progeny expressing p35 from
adenoviral (left panel) or plasmid (right panel) vectors. (F) Semi-quantitative image analysis of fold change in CRMP2 phosphorylation at the
CDK5 epitope (Ser522) in immunoblots from cells expressing p35 from adenoviral or plasmid vectors. * p < 0.05 compared to vehicle-treated
controls by one-way ANOVA with post-hoc Dunnett’s test. Scale bar = 10 μm.
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of abnormal CDK5 activity in NPC-derived neural pro-
geny over-expressing p35, we performed western blot
screening with a panel of antibodies specific for different
phosphorylated forms of CRMP2 and related proteins
(CRMP4, CRMP1) or total non-phosphorylated forms
(Table 1). This analysis confirmed that CRMP2 was
hyperphosphorylated at the CDK5-specific epitope
(Ser522) in total cell lysates from NPC-derived neural
progeny overexpressing p35 compared to control cul-
tures (Figure 1D-F). Increased phosphorylation was also
detected at other residues in the C-terminal tail of
CRMP2 (Thr509/Thr514) (Figure 1D), however since
previous reports have shown that phosphorylation by
CDK5 at the Ser522 residue is required as a priming
step before GSK3b-mediated phosphorylation at the
nearby Thr residues can occur [25,27,28], we focused
our investigations on the CDK5-specific epitope at
Ser522. Total levels of CRMP2 were unchanged in cells
overexpressing p35 compared to control cells, and other
related proteins from the CRMP family were not differ-
entially phosphorylated under these conditions of CDK5
activation (Figure 1D).
For confirmation that the observed increase in
CRMP2 phosphorylation was not due to virus-specific
effects, we performed similar experiments using an
alternative vector for p35 overexpression. For this pur-
pose, we performed immunoblot analysis in parallel
with NPC-derived neural cells infected with p35-adv or
cells transfected with a plasmid expressing myc-tagged
p35. We found that phosphorylation of the CDK5 epi-
tope Ser522-CRMP2 was significantly upregulated in
cells overexpressing p35 via both adenoviral vector or
plasmid transfection compared to uninfected controls
(Figure 1E,F). For all subsequent experiments, results
shown are from experiments where untagged p35 was
overexpressed using the adenoviral vector.
To further verify that CRMP2 is a target of p35-
mediated abnormal activation of CDK5, we used siRNA
to knock down expression of the endogenous CRMP2
protein (siCRMP2), and performed immunoblot analysis
to assess levels of pSer522-CRMP2 and total CRMP2
(Additional File 1, Figure S1). We found that transfec-
tion with siCRMP2 decreased total levels of CRMP2
expression by approximately 80% compared to controls
in both untreated and p35-expressing NPC-derived
neural progeny (Additional File 1, Figure S1 A,B). More-
over, transfection with siCRMP2 dramatically reduced
levels of pSer522-CRMP2 by over 90% in control cells,
and completely reversed the hyperphosphorylation of
C R M P 2i n d u c e db yp 3 5e x p r e s s i o ni nN P C - d e r i v e d
neural progeny (Additional File 1, Figure S1 A,C).
Taken together, these studies confirmed that CRMP2
was hyperphosphorylated at the CDK5-specific residue
(Ser522) under conditions of abnormal CDK5 activation.
CRMP2 phosphorylation can be reversed in vitro with
pharmacological or genetic down-regulation of CDK5
Our previous observations showed that abnormal CDK5
activation in NPC-derived neural progeny impaired
neurite outgrowth and cell maturation [17] (Figure 1).
Moreover, down-regulating CDK5 activity or expression
reversed the neurite outgrowth deficits [17]. In order to
determine whether CDK5-mediated CRMP2 phosphory-
lation might contribute to these effects, we used a phar-
macological inhibitor of CDK5 (Roscovitine) or an
siRNA-based approach to down-regulate CDK5 activity
or expression, respectively, and assessed levels of
CRMP2 phosphorylation by immunocytochemistry and
immunoblot. For this purpose, differentiating NPCs
were pre-treated with Roscovitine, or transfected with
siRNA targeting CDK5 for 6 hrs, followed by infection
with adenovirus expressing p35. We have previously
qualified and tested the siRNA targeting CDK5 for
Table 1 Antibodies tested and reactive epitopes against phosphorylated and total CRMP proteins.
Antibody Epitope Company Species Reactivity
CRMP2 pThr514 Cell Signaling Rabbit Human, mouse, rat
CRMP2 pThr514 Kinasource Sheep Human, mouse
CRMP2 pThr509, pThr514 Kinasource Sheep Human, mouse, rat
CRMP2 pSer522 ECM Biosciences Rabbit Human, mouse, rat
CRMP2 pSer522 Kinasource Sheep Human, mouse, rat
CRMP2 pThr555 ECM Biosciences Rabbit Human, mouse, rat
CRMP2 total (C-terminus) ECM Biosciences Rabbit Human, mouse, rat
CRMP2 total (peptide) Millipore Rabbit Rat
CRMP2 total (recombinant) Kinasource Sheep Human, mouse CRMP1,2,4
CRMP1 pThr509 Kinasource Sheep Human
CRMP4 pThr509 Kinasource Sheep Human, mouse, rat
CRMP4 (TUC4) total (peptide) Millipore Rabbit Human, mouse, rat
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sequences [17].
Notably, under conditions of reduced CDK5 activity or
expression in p35-expressing NPC-derived neural pro-
geny, reduced levels of CRMP2 phosphorylation were
detected, as demonstrated by immunocytochemical (Fig-
ure 2A-G) and immunoblot analyses (Figure 2H,I) with
an antibody against pSer522-CRMP2. Roscovitine treat-
ment in the absence of p35 over-expression does not
appear to have a significant effect on levels of CRMP2
phosphorylation (Figure 2). It is possible that this could
be due to alternative kinases phosphorylating CRMP2,
however as CDK5 is the only kinase known at this time
to phosphorylate CRMP2 at Ser522, another mechanism
Figure 2 Down-regulation of CDK5 reduces CRMP2 phosphorylation in NPC-derived neural progeny. Differentiating NPCs were treated
on day 2 with the pharmacological inhibitor Roscovitine (Rosco) or siRNA against CDK5 (siCDK5), followed by infection with p35-adenovirus. On
day 4, NPC-derived neural progeny were fixed for immunofluorescence or lysed for immunoblot analysis. (A-C) Immunocytochemical analysis
with an antibody against pSer522-CRMP2 showed low levels of endogenous immunoreactivity in uninfected, vehicle-treated cells (A), with a
slight reduction in cells treated with Roscovitine (B) or siCDK5 (C). (D-F) NPC-derived neural progeny expressing p35 showed a notable increase
in CRMP2 phosphorylation (D) that was reversed by treatment with Rosco (E) or siCDK5 (F). (G) Reversal of CRMP2 hyperphosphorylation with
CDK5 down-regulation. (H) Immunoblot analysis of pSer522-CRMP2, total (t)CRMP2, CDK5, and actin as a loading control. (I) Semi-quantitative
image analysis of levels of CRMP2 phosphorylation in NPCs infected with p35-adv with or without Rosco or siCDK5. * p < 0.05 compared to
vehicle-treated controls by one-way ANOVA with post-hoc Dunnett’s test. # p < 0.05 compared to p35-expressing NPCs by one-way ANOVA
with post-hoc Tukey-Kramer test. Scale bar = 10 μm.
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Ser522-phosphorylated CRMP2 is highly resistant to
desphosphorylation by protein phosphatases [29]. There-
fore, it is likely that the CRMP2 that is already phos-
phorylated by basal CDK5 activity prior to roscovitine
treatment remains phosphorylated and stable, while ros-
covitine treatment of cells with exogenous p35 expres-
sion more effectively modulates levels of CRMP2
phosphorylation at the Ser522 residue. Taken together,
these results support the possibility that abnormal
CDK5 activation targets CRMP2 for hyperphosphoryla-
tion, and this can be reversed by down-modulating
abnormal CDK5 activity.
Expression of a non-phosphorylatable CRMP2 construct
reduces CRMP2 phosphorylation and rescues neurite
outgrowth defects in adult NPCs with abnormal CDK5
activation
In order to determine whether CRMP2 phosphorylation
is directly related to the neurite outgrowth defects
observed in our cellular model of abnormal CDK5 acti-
vation in adult neurogenesis, we utilized site-directed
mutagenesis to generate a construct encoding a mutant
(S522A) form of CRMP2 (S522A-CRMP2) that is not
phosphorylatable by CDK5 at the Ser522 epitope (Addi-
tional File 1, Figure S2 A). Immunoblot analysis con-
firmed that transfection of differentiating NPCs with the
S522A-CRMP2 construct or WT-CRMP2 resulted in
similar levels of total CRMP2 expression (Additional
File 1, Figure S2 B). In contrast, levels of pSer522-
C R M P 2i m m u n o r e a c t i v i t yw e r ec o n s i d e r a b l yl o w e ri n
NPC-derived neural progeny expressing S522A-CRMP2
compared to WT-CRMP2-transfected controls (Addi-
tional File 1, Figure S2 B,C). Controls including trans-
fection agent (Lipofectamine) alone or CMV-GFP vector
control showed that levels of pSerCRMP2 and total
CRMP2 immunoreactivity were similar to non-trans-
fected controls (Additional File 1, Figure S2 B,C).
In order to assess whether down-regulating CDK5-
mediated phosphorylation of CRMP2 at Ser522 by
expression of a mutant construct might have a protec-
tive effect on the neurite alterations observed in NPC-
derived neural progeny with abnormal CDK5 activity,
neurite outgrowth analysis was performed in cultured
cells immunolabeled with an antibody against b-Tubulin
(Figure 3A-F). This demonstrated that expression of the
mutant S522A-CRMP2 construct rescued the neurite
deficits in NPC-derived neural progeny expressing p35,
whereas expression of the WT-CRMP2 construct was
not protective under these conditions (Figure 3A-G).
Immunoblot analysis confirmed that expression of
S522A-CRMP2 reduced levels of CRMP2 phosphoryla-
tion in p35-expressing NPC-derived neural progeny
compared to WT-CRMP2. We detected a slight
apparent increase in pSer-CRMP2 immunoreactivity in
lysates from cells expressing the non-phosphorylatable
mutant S522A-CRMP2 construct. Higher resolution gel
electrophoresis studies indicated that while CRMP2
hyperphophorylation induced by p35 overexpression
resulted in a gel mobility shift that was consistent with
a change in phosphorylation state [27], no such shift
was detected with overexpression of the S522A-CRMP2
mutant construct (data not shown). It is possible that
the apparent increase in immunoreactivity with S522A-
CRMP2 over-expression could be due to a mild change
in protein folding induced by the mutation, causing a
slight affinity of the pSerCRMP2 antibody for the
mutant unphosphorylated human protein. Levels of total
CRMP2 were similar in cells transfected with either the
WT or mutant constructs (Figure 3H,I). Levels of
CRMP2 phosphorylation were expressed as ratios of
pCRMP2/tCRMP2 immunoreactivity because overex-
pression of the CRMP2 constructs increases total levels
of CRMP2. Since over-expression of WT-CRMP2 is
known to promote neurite outgrowth in neuronal cell
lines [30], when WT-CRMP2 is overexpressed and
phosphorylation is increased, there are increased quanti-
ties of both total and phospho-CRMP2. Thus, under
conditions of CRMP2 overexpression, the ratio of phos-
pho-CRMP2/total-CRMP2 may be the most accurate
representation of relative CRMP2 phosphorylation that
impacts neurite outgrowth. Taken together, these data
support the possibility that phosphorylation of CRMP2
by CDK5 at the Ser522 epitope contributes to impaired
neurite outgrowth under conditions of abnormal CDK5
activation in cultured NPCs.
Tubulin distribution and microtubule organization are
disturbed in NPC-derived neural progeny with abnormal
CDK5 activation
Previous studies have shown that phosphorylation of
CRMP2 regulates its interactions with tubulin heterodi-
mers [30]. In light of our observations thus far, it is pos-
sible that CDK5-mediated hyperphosphorylation of
CRMP2 in our in vitro model might impair neurite out-
growth by disrupting microtubule polymerization in
developing neuronal processes. First, to assess the distri-
bution of polymerized tubulin in live cell cultures,
Tubulin Tracker reagent was applied to NPC-derived
neural progeny after four days of differentiation under
control and activated CDK5 conditions (Figure 4A,B). In
cultures infected with p35-adv, reduced neurite com-
plexity was apparent compared to uninfected controls.
Furthermore, under control conditions, the distribution
of polymerized tubulin appeared to be localized to cell
processes, and characterized by well-defined bundled
tubulin fibers (Figure 4A). In contrast, under conditions
of abnormal CDK5 activation, the polymerized tubulin
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mesh-like tubulin fibers localized to the cytoplasm in
cells infected with p35-adv (Figure 4B).
To further investigate the underlying ultrastructural
basis of the neurite alterations observed in p35-overex-
pressing NPC-derived neural progeny, cells on
coverslips were fixed in glutaraldehyde and analyzed by
electron microscopy (Figure 4C-F). These studies
showed that control NPC-derived neural progeny dis-
played long electron-dense microtubule structures dis-
tributed along neuritic processes in a parallel,
organized arrangement (Figure 4C,D). In contrast, in
Figure 3 Expression of S522A-CRMP2 mutant construct rescues neurite deficits in p35-expressing NPC-derived neural progeny.
Differentiating NPCs were transfected on day 2 with wild-type (WT) human CRMP2 or mutated S522A-CRMP2 plasmids, followed by infection
with p35 adenovirus. Cells were fixed on day 4 of differentiation with glutaraldehyde for b-tubulin immunofluorescence, or lysed for immunoblot
analysis. (A-F) Immunocytochemical analysis of b-tubulin immunoreactivity showed reduced b-tubulin-positive neurites in NPC-derived neural
progeny infected with p35-adv with or without co-expression of WT-CRMP2, and rescue with co-expression of S522A-CRMP2 plasmid. (G) Image
analysis showing reduced b-tubulin-positive neurite lengths in p35-expressing and p35+WT-CRMP2 NPC-derived neural progeny that was
recovered after co-expression of p35 and S522A-CRMP2. (H) Immunoblot analysis showing levels of CRMP2 phosphorylation in p35-expressing
NPC-derived neural progeny transfected with S522A-CRMP2 or WT-CRMP2 plasmid. (I) Semi-quantitative image analysis of ratios of pSer522-
CRMP2 (pCRMP2)/total CRMP2 (tCRMP2) levels in NPC-derived neural progeny expressing p35 with and without WT-CRMP2 or S522A-CRMP2 co-
expression. * p < 0.05 compared to vehicle-treated controls by one-way ANOVA with post-hoc Dunnett’s test. # p < 0.05 compared to WT-
CRMP2-transfected NPCs by one-way ANOVA with post-hoc Tukey-Kramer test. Scale bar = 25 μm, 10 μm (insets).
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progeny, filamentous and tubule-like structures were
less abundant, and those that were observed were
shorter and more disorganized than in control cells
(Figure 4E,F). These results support the possibility that
abnormal activation of CDK5 and hyperphosphoryla-
tion of CRMP2 during neurogenesis in neurodegenera-
tive disorders might impair microtubule
polymerization and disrupt the organization of these
important structural components of the cytoskeleton.
NPC-derived neural progeny with abnormal CDK5
activation show impaired microtubule polymerization
following exposure to microtubule destabilizing agents
To further investigate the process of microtubule poly-
merization in NPC-derived neural progeny, we per-
formed a series of nocodazole washout experiments to
visualize the formation of microtubules over a period of
10-30 mins. For this purpose, NPC-derived neural pro-
geny were incubated with nocodazole for 3 hrs, followed
by no washout, or washout for 10-30 mins (Figure 5A-
Figure 4 Live-cell imaging of polymerized tubulin distribution, and ultrastructural analysis of microtubules in NPC-derived neural
progeny with CDK5 activation. Differentiating NPCs were infected on day 2 with an adenoviral vector expressing p35. For live imaging of
tubulin distribution, on day 4, cells on coverslips were incubated with Tubulin Tracker Green to stain polymerized tubulin. Coverslips were
imaged using a fluorescent microscope. For electron microscopy analysis, NPCs were grown on coverslips embedded in 35 mm dishes, fixed in
glutaraldehyde and processed for electron microscopic analysis. (A,B) Live-cell imaging of polymerized tubulin stained with Tubulin Tracker in cell
bodies and processes of NPC-derived neural progeny infected with p35-adv. (A) Under control conditions, polymerized tubulin is apparent in
bundled microtubule structures in cell processes (arrows). (B) Under conditions of abnormal CDK5 activation, polymerized tubulin staining was
primarily detected in diffuse, cytoplasmic fibers (arrows). (C,D) Electron microscopy images showing organized cytoskeletal structure in control
NPC-derived neural progeny with long, parallel tubule structures (arrows) along the processes of cells. (E,F) NPC-derived neural progeny
expressing high levels of p35 displayed a disorganized cytoskeleton with less abundant, short and web-like filamentous structures (arrows) in the
processes of cells. Scale bar = 30 μm (A,B); 0.5 μm (C,E); 0.25 μm (D,F).
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tion to allow visualization of intact microtubules, then
processed for b-tubulin immunofluorescence and
imaged on a fluorescent microscope. This showed, as
expected, that directly following nocodazole treatment
(no washout), both control and p35-expressing NPC-
derived neural progeny displayed a dramatic reduction
of b-tubulin immunoreactivity, and microtubule struc-
ture was almost completely ablated in both groups (Fig-
ure 5A,C). Twenty minutes after nocodazole washout, in
both control and NPC-derived neural progeny expres-
sing high levels of p35, we observed the appearance of
perinuclear microtubule organizing centers (Figure 5B,
D).
By 20 minutes post-washout, control nocodazole-trea-
ted cultures (Figure 5B) regained approximately 75% of
the neurite lengths compared to untreated control cul-
tures (Figure 5E), while p35-expressing cells only dis-
played diffuse b-tubulin immunoreactivity in processes
(Figure 5D), and no significant increase in neurite
lengths (Figure 5E). Only very fine processes were
detected under these conditions up to 30 minutes post-
washout (data not shown). These results are consistent
with the possibility that abnormal activation of CDK5 in
the pathogenesis of neurodegenerative disorders might
disrupt adult neurogenesis by impairing microtubule
polymerization and neurite outgrowth.
Increased CRMP2 phosphorylation in a model of HIV-
protein mediated activation of CDK5 in adult
neurogenesis, and reversal with CDK5 siRNA
We and others have shown that CDK5 signaling is dys-
regulated in patients with HIVE and in animal and in
vitro models of HIV-associated neurotoxicity [8,31].
These studies demonstrate that the HIV protein gp120
contributes to calpain-mediated activation of CDK5 and
downstream hyperphosphorylation of CDK5 substrates
such as tau in mature neuronal populations [8,31]. In
this context, we sought to examine the possibility that
HIV proteins could modulate CRMP2 phosphorylation
in a similar manner to what we observed in our in vitro
model of p35-directed abnormal CDK5 activation in
adult neurogenesis. For this purpose, NPC-derived
neural progeny were exposed to recombinant HIV-
gp120 protein for 24 hrs on day 3 of differentiation.
Double-immunolabeling analysis with antibodies against
Figure 5 Tubulin polymerization is impaired in p35-expressing NPC-derived neural progeny following chemical microtubule
disruption. For chemical disruption of microtubules, cultures were treated with 5 μg/mL nocodazole (Noc) for 3 hr, followed by washout and
incubation in fresh differentiation media for 20 mins. NPC-derived neural progeny were fixed with glutaraldehyde and processed for b-tubulin
immunofluorescence. (A,B) Chemically-induced disruption of microtubule structure in nocodazole-treated control NPC-derived neural progeny (A)
was recovered by 20 mins post-washout (B). (C,D) Disruption of microtubule structure in nocodazole-treated p35-expressing NPC-derived neural
progeny (C) appeared unchanged by 20 mins post-washout (D). (E) Quantitative image analysis of neurite outgrowth in NPC-derived neural
progeny following treatment with nocodazole. Untreated control is shown for comparison to baseline neurite lengths. * p < 0.01 compared to
vehicle-treated controls by one-way ANOVA with post-hoc Dunnett’s test; # p < 0.01 compared to nocodazole-treated controls by one-way
ANOVA with post-hoc Tukey-Kramer test. Scale bar = 15 μm.
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Page 9 of 22the immature neuronal marker b-III Tubulin and
pSer522-CRMP2 revealed that gp120 treatment resulted
in upregulated CRMP2 phosphorylation, and this effect
was accompanied by reduced b-III Tubulin immunor-
eactivity (Figure 6A-F,M,N). siRNA experiments to
knock down CDK5 expression showed that these effects
could be rescued by down-modulating CDK5 expression
(Figure 6G-N). Similar to what we observed previously
using the CDK5-targeting siRNA (Figure 2 and [17]), in
NPCs expressing CDK5 siRNA alone or in combination
with gp120 treatment, CDK5 levels were reduced by
approximately 50-60% (data not shown). Taken together,
these studies in an in vitro model of adult neurogenesis
reveal that abnormal activation of CDK5 mediated by
either p35 overexpression or HIV-gp120 treatment
triggers hyperphosphorylation of CRMP2, which may
contribute to microtubule destabilization and impaired
neurogenesis and neuronal maturation in the mature
brain.
CRMP2 phosphorylation is increased and dendritic
maturation is impaired in primary neuronal cultures with
abnormal CDK5 activation
Since our results in NPC-derived neural progeny suggest
that abnormal CDK5 activation and hyperphosphoryla-
tion of CRMP2 contributes to impaired neurite out-
growth during neurogenesis, we sought to determine
whether these factors might also play a role in neurite
maturation in mature neuronal cells. For this purpose,
we infected primary rat hippocampal neurons with p35-
Figure 6 Increased CRMP2 phosphorylation in NPCs treated with HIV-gp120 protein, and rescue with CDK5 siRNA knockdown.
Differentiating NPCs were transfected day 2 of differentiation with siRNA specific for CDK5 (siCDK5) or transfection reagent control, followed by
treatment with recombinant HIV-gp120 protein (100 ng/mL) or vehicle control. Cells were fixed on day 4 of differentiation for double-
immunolabeling analysis with antibodies against b-III Tubulin (immature neuronal marker) and pSer522-CRMP2 (pSer-CRMP2). (A-C) b-III Tubulin-
positive NPC-derived neuronal progeny treated with vehicle control express background levels of pSer-CRMP2. (D-F) NPC-derived neuronal
progeny treated with gp120 for 48 hrs display increased pSer-CRMP2 immunoreactivity in b-III Tubulin-positive cells. (G-I) b-III Tubulin-positive
NPC-derived neuronal progeny treated with siCDK5 show low levels of pSer-CRMP2 immunoreactivity. (J-L) b-III Tubulin-positive NPC-derived
neuronal progeny treated with siCDK5 and gp120 show background levels of pSer-CRMP2 immunoreactivity. (M, N) Semi-quantitative image
analysis of b-III Tubulin (M) and pSer-CRMP2 (N) immunoreactivity. * p < 0.05 compared to vehicle-treated controls by one-way ANOVA with
post-hoc Dunnett’s test. Scale bar = 20 μm.
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tion and dendritic integrity were analyzed by immuno-
cytochemistry and immunoblot. Similar to NPC-derived
neural progeny, primary hippocampal neurons overex-
pressing p35 displayed increased pSer522-CRMP2
immunoreactivity compared to uninfected controls (Fig-
ure 7A-F, M-P). Interestingly, under control conditions,
primary neurons expressed higher levels of pSer522-
CRMP2 than NPCs, and thus the change in pSer522-
CRMP2 immunoreactivity with p35 overexpression was
less dramatic in primary neuronal cultures than in
NPCs (40-50% increase in CRMP2 phosphorylation in
primary neurons compared to 3-4 fold in NPC-derived
neural progeny). However, similar to what was observed
in NPCs, in primary neurons increased p35 expression
and CRMP2 phosphorylation was accompanied by
reduced neurite maturation and dendritic complexity, as
shown by immunolabeling with an antibody against
microtubule-associated protein-2 (MAP2, dendritic mar-
ker) (Figure 7A-F, M, N). Similar effects were observed
in primary neuronal cultures exposed to HIV-gp120
protein for 24 hrs alone or in combination with p35
overexpression (Figure 7G-P). Under these conditions,
extensive damage to MAP2-immunoreactive processes
was visible, and pSer522-CRMP2 immunoreactive
deposits were detected in varicosities along the neuronal
processes (Figure 7G-L). Taken with the observations
from experiments with NPC-derived neural progeny,
these results suggest that abnormal CDK5 activation
and subsequent CRMP2 hyperphosphorylation may have
deleterious effects on neurite outgrowth in both imma-
ture and mature neuronal populations in the adult
brain. Thus, the role of CRMP2 hyperphosphorylation
in neurodegenerative disorders where abnormal CDK5
activation contributes to the pathogenesis of the disease
warrants investigation.
CRMP2 is hyperphosphorylated in the brains of patients
with HIVE
To further evaluate the potential contribution of
CRMP2 to neurogenic alterations in the pathogenesis of
HIV in the brain, we examined expression levels and
patterns of immunoreactivity of CRMP2 in the hippo-
campus of HIV patients with and without encephalitis
(patient demographics and clinic-pathological character-
istics presented in Table 2). In support of a role for
CRMP2 in the neurogenic niche of the adult hippocam-
pus, double-labeling immunocytochemical analysis with
antibodies against doublecortin (DCX, a marker of
immature neuroblasts) and CRMP2 revealed that
CRMP2 is expressed throughout the hippocampal DG
in the brains of patients with HIVE (Figure 8A-C). A
subset of cells in the subgranular zone (SGZ) co-
expressed both DCX and CRMP2, suggesting that
endogenous neuronal progenitor cells in the adult hip-
pocampus could be sensitive to CDK5-mediated hyper-
phosphorylation of CRMP2 (Figure 8A-C).
To determine whether CRMP2 phosphorylation or
expression is altered in the brains of patients with
HIVE, immunocytochemical analysis was performed
with antibodies against total CRMP2 and pSer522-
CRMP2 in hippocampal sections from HIV+ (no ence-
phalitis) and HIVE brains (Figure 9). Both total CRMP2
and pSer522-CRMP2 displayed a granular expression
pattern in the granular cell layer and subgranular zone
of the hippocampal dentate gyrus. Consistent with our
previous report that CDK5 expression and activity is
increased in the brains of patients with HIVE [8], image
analysis revealed that overall CRMP2 and phosphory-
lated CRMP2 (Ser522 epitope) levels were significantly
increased in the hippocampus of HIVE brains compared
to HIV+ controls without encephalitis (Figure 9A-J).
Numerous intensely CRMP2-immunoreactive nuclear
profiles were also detected in the SGZ of HIVE brains
(Figure 9D,I), suggesting that in the pathogenesis of
HIVE, cells in this neurogenic region are sensitive to
CDK5-mediated upregulation of CRMP2
phosphorylation.
To further examine overall expression levels of
CRMP2 in the brains of HIVE patients, immunoblot
analysis was performed with brain homogenates from
HIV+ (no encephalitis) controls and HIVE patients
(Additional File 1, Figure S3). This analysis revealed that
levels of phosphorylated (Ser522) CRMP2 were signifi-
cantly upregulated in HIVE patients compared to non-
encephalitic HIV+ controls (Additional File 1, Figure S3
A , B ) .I nf a c t ,w h i l es o m en o n - e n c e p h a l i t i sc a s e sd i s -
played only very low levels of immunoreactivity with the
pSer522-CRMP2 antibody, every one of the HIVE cases
examined showed robust pSer522-CRMP2 immunoreac-
tivity by immunoblot (Additional File 1, Figure S3 A).
Hyperphosphorylated CRMP2 is detected in the brains of
gp120 tg mice, and is reversed with genetic down-
modulation of CDK5 expression
Similar to what we observed in the hippocampus of
HIVE patients, CRMP2 and pSer522-CRMP2 immunor-
eactivity were detected throughout the DG in immuno-
labeled sections from the brains of non-transgenic
(nontg) and gp120 tg mice (Figure 10). In support of a
role for CRMP2 in this neurogenic region, double-label-
ing immunocytochemical analysis with antibodies
against DCX and CRMP2 revealed that CRMP2 is
expressed throughout the hippocampal DG in the brains
of gp120 tg mice (Figure 8D-F). Levels of total CRMP2
and pSer522-CRMP2 immunoreactivity were increased
in the hippocampus of gp120 tg mice compared to
nontg controls (Figure 10A,B,E,F,G,J), indicating that
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Page 11 of 22Figure 7 CRMP2 is hyperphosphorylated and dendritic development is impaired in primary neurons over-expressing p35 alone or in
combination with HIV-gp120 protein treatment. Primary rat hippocampal neurons were infected two days after plating with p35-adv,
followed by treatment with recombinant HIV-gp120 protein or vehicle control. Cells were fixed on day 4 of differentiation for double-
immunolabeling analysis with antibodies against MAP2 (dendritic marker) and pSer522-CRMP2 (pSer-CRMP2). (A-C) MAP2-positive primary
neurons treated with vehicle control express background levels of pSer-CRMP2. (D-F) Primary neurons infected with p35-adv display increased
pSer-CRMP2 immunoreactivity and reduced MAP2-immunoreactive dendrites. (G-I) Primary neurons treated with recombinant HIV-gp120 display
increased pSer-CRMP2 immunoreactivity and reduced MAP2-immunoreactive dendrites, with an accumulation of pSer-CRMP2 immunoreactivity
in varicosities along the neuronal processes (arrows). (J-L) Primary neurons infected with p35-adv and treated with recombinant HIV-gp120
display increased pSer-CRMP2 immunoreactivity and extensive damage to MAP2-immunoreactive dendrites, with an abundant accumulation of
pSer-CRMP2 immunoreactivity in varicosities along the neuronal processes (arrows). (M, N) Semi-quantitative image analysis of pSer-CRMP2 (M)
and MAP2 (N) immunoreactivity. (O) Immunoblot analysis of total cell lysates showing increased CRMP2 phosphorylation in primary hippocampal
neurons infected with p35-adv or treated with HIV-gp120 protein. (P) Semi-quantitative image analysis of fold change in CRMP2 phosphorylation
at the CDK5 epitope (Ser522) in immunoblots from cells expressing p35-adv or treated with gp120. * p < 0.05 compared to vehicle-treated
controls by one-way ANOVA with post-hoc Dunnett’s test. Scale bar = 20 μm.
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phosphorylation of CRMP2.
In our in vitro model of abnormal CDK5 activation in
NPC-derived neural progeny, we found that CDK5-
directed CRMP2 hyperphosphorylation could be
reversed by knocking down CDK5 expression or activity
(Figure 2). Therefore, we sought to determine if this
effect could also be rescued in vivo in gp120 tg mice
crossed with a CDK5 heterozygous-deficient (CDK5+/-)
line. Immunocytochemical analysis revealed that this
w a st h ec a s e ,a sg p 1 2 0t g / C D K 5 + / -a n i m a l sd i s p l a y e d
levels of CRMP2 (Figure 10A-E) and pSer522-CRMP2
(Figure 10F-J) immunoreactivity that were comparable
to nontg controls.
Discussion
Abnormal CDK5 activity has been shown to contribute
to neurotoxicity during the pathogenesis of several neu-
rodegenerative disorders, including HIV neurotoxicity,
AD, and prion-related encephalopathies. In the progres-
sion of these disorders, activation of CDK5 may trigger
a cascade of hyperphosphorylation of downstream tar-
gets, and subsequent modulation of critical cellular
functions. Most studies have focused on the role of tau
hyperphosphorylation in mediating the neurodegenera-
tive effects of CDK5 and other aberrantly activated
kinases in mature neurons [8,32,33]. However, consider-
ing the myriad substrates phosphorylated by CDK5,
other downstream targets may be involved, particularly
in distinct functions such as neurogenesis and neuronal
maturation. In this context, we report that dysregulation
of the growth cone signaling protein CRMP2 by
Table 2 Demographic and clinico-pathological characteristics of HIV+ cases with and without HIV encephalitis.
Neuropathology diagnosis Age Gender PM time (hrs) Brain weight Cause of Death
Normal 55 M 25 1220 Heart failure
Normal 53 M 18 1410 Respiratory failure
Normal 47 M 12 1200 Bronchopneumonia
Normal 35 M 9 1440 Hypotensive shock
Normal 36 F 24 1370 Respiratory failure
Normal 49 M 30 1350 Cryptococcal pneumonia
Normal 54 M 14 1220 Cardiac infarction
Normal 67 M 15 1440 Complications of HIV and HCV co-infection
HIV encephalitis 34 M 30 1120 Heart failure
HIV encephalitis 39 M 19 1370 Organ failure
HIV encephalitis 37 M 5 1510 Respiratory failure
HIV encephalitis 55 M 15 1040 Bacterial pneumonia
HIV encephalitis 41 M 12 1230 Cachexia
HIV encephalitis 43 M 6 1350 AIDS
HIV encephalitis 47 M 47 1260 Sepsis
HIV encephalitis 43 M 72 1410 Undetermined
PM = post-mortem time, HCV = Hepatitis C virus
Figure 8 Patterns of CRMP2 immunoreactivity in the
hippocampus of an HIV encephalitis brain and a gp120
transgenic mouse brain. Forty μm-thick vibratome sections from
the brains of HIV encephalitis (HIVE) patients and gp120 transgenic
(tg) mice were processed for double-immunolabeling analysis with
antibodies against doublecortin (DCX) and CRMP2. (A-C) Intracellular
CRMP2 immunoreactivity was detected throughout cells in the
granular cell layer (GCL) and into the molecular layer (ML) of the
hippocampal dentate gyrus in a representative section from the
brain of a patient with HIVE. A subset of DCX-positive cells in the
subgranular zone (SGZ) co-expressed CRMP2 (arrows). (D-F)
Intracellular CRMP2 immunoreactivity was detected throughout cells
in the granular cell layer (GCL) and into the molecular layer (ML) of
the hippocampal dentate gyrus in a representative section from the
brain of a gp120 tg mouse. A subset of DCX-positive cells in the
subgranular zone (SGZ) co-expressed CRMP2 (arrows). Scale bar =
15 μm.
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Page 13 of 22Figure 9 Increased CRMP2 expression and phosphorylation in the hippocampus of patients with HIV encephalitis.F o r t yμm-thick
vibratome sections from the hippocampus of HIV+ control and HIV encephalitis (HIVE) patients were processed for immunolabeling analysis with
antibodies against CRMP2 and pSer522-CRMP2 (pSer-CRMP2). Low power images show overall immunoreactivity throughout the hippocampus,
including the CA1-4 regions, the dentate gyrus (DG) and the subgranular zone (SGZ), and high power images show more detail of the DG
including the SGZ and granular cell layer (GCL). (A-D) Patterns of total CRMP2 immunoreactivity in the hippocampus from representative HIV+
non-encephalitis (control) and HIVE brains at low (A, C) and high (B, D) power. Numerous intensely immunoreactive cell profiles were detected
in the SGZ (arrows), particularly in the brains of HIVE patients. (E) Semi-quantitative image analysis of CRMP2 immunoreactivity in the
hippocampal DG of HIV patients. (F-I) Patterns of pSer-CRMP2 immunoreactivity in the hippocampus from representative HIV+ non-encephalitis
(control) and HIVE brains at low (F, H) and high (G, I) power. (J) Semi-quantitative image analysis of pSer-CRMP2 immunoreactivity in the
hippocampal DG of HIV patients. * p < 0.05 compared to HIV+ controls by unpaired two-tailed Student’s t-test (n = 8 per group). Scale bar =
200 μm (A,C,F,H); 30 μm (B,D,G,I).
Figure 10 Increased CRMP2 phosphorylation in gp120 transgenic mice is rescued with down-modulation of CDK5 expression.F o r t y
μm-thick vibratome sections from the brains of 8-month old non-transgenic (nontg), gp120 transgenic (tg), CDK5 heterozygous-deficient (CDK5
+/-), and gp120 tg/CDK5+/- mice were processed for immunolabeling analysis with antibodies against CRMP2 and pSer522-CRMP2 (pSer-CRMP2).
(A-D) Patterns of total CRMP2 immunoreactivity in the dentate gyrus from representative mouse brains showing a punctate expression pattern
throughout the granular cell layer (GCL) and subgranular zone (SGZ), with background immunoreactivity detected in the molecular layer (ML).
Intensely immunoreactive cell profiles were detected in the SGZ (arrows), particularly in the brains of gp120 tg mice. (E) Semi-quantitative image
analysis of CRMP2 immunoreactivity in the hippocampal DG of nontg, gp120 tg, CDK5+/- and gp120 tg/CDK5+/- mice. (F-I) Patterns of pSer-
CRMP2 immunoreactivity in the hippocampal DG from representative mouse brains showing a punctate expression pattern throughout the
granular cell layer (GCL) and subgranular zone (SGZ), with background immunoreactivity detected in the molecular layer (ML). Intensely
immunoreactive cell profiles were detected in the SGZ (arrows), particularly in the brains of gp120 tg mice. (J) Semi-quantitative image analysis
of pSer-CRMP2 immunoreactivity in the hippocampus of nontg, gp120 tg, CDK5+/- and gp120 tg/CDK5+/- mice. * p < 0.05 compared to nontg
controls by one-way ANOVA with post-hoc Dunnett’s test (n = 4 per group). Scale bar = 30 μm.
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Page 14 of 22abnormal CDK5 activation in an in vitro model of adult
neurogenesis contributes to defective neurite outgrowth
during neuronal maturation. Down-regulation of CDK5
activity with the pharmacological inhibitor Roscovitine
or siRNA knockdown, or expression of a non-phosphor-
ylatable CRMP2 mutant construct (S522A) rescued the
neurite defects associated with abnormal activation of
CDK5 in NPC-derived neural progeny.
In support of a role for CRMP2 in neurodegenerative
pathways, previous studies have revealed that CRMP2 is
hyperphosphorylated as a result of abnormal CDK5
activity in the brains of AD patients and in a transgenic
mouse model of AD [20]. In AD brains, phosphorylated
CRMP2 associates with damaged neurites and neurofi-
brillary tangles [21,22,34], and accumulates in neurons
surrounding cortical amyloid plaques [35]. More
recently, several proteomics-based studies in the brains
of human HIV patients have identified differential
expression of CRMP2 in cases with HIVE or HIV-asso-
ciated dementia [23,24]. The present study reveals that
levels of total and phosphorylated (Ser522) CRMP2 were
significantly increased in neurogenic sites of the hippo-
campus from HIVE patients compared to non-encepha-
litic HIV+ controls, and similar results were observed in
a mouse model of HIV-gp120 neurotoxicity. While the
present study was focused on the effects of CDK5 acti-
vation and CRMP2 alterations in the neurogenic region
of the hippocampus, it is of interest that we observed
cells throughout the SGZ and the granular cell layer dis-
playing increased CRMP2 immunoreactivity and phos-
phorylation, particularly in the gp120 tg mouse model.
This suggests that mature neuronal cell populations in
addition to NPCs may be vulnerable to CDK5-mediated
abnormal CRMP2 phosphorylation. Our results in pri-
mary hippocampal neurons also support this possibility,
however future studies in other mature neuronal cell
types and alternative brain regions (e.g. cortex) will be
necessary to elucidate whether CDK5-mediated altera-
tions in CRMP2 is a common pathological feature of
HIV-associated neurodegeneration.
In the tg mouse model, hippocampal CRMP2 hyper-
phosphorylation was reversed with genetic down-modu-
lation of CDK5. Since CDK5 activity and
phosphorylation of other substrates in mature neurons
is increased in models of HIV neurotoxicity [8], under
these conditions, heterozygous CDK5 deficiency may be
protective by normalizing the activity of CDK5 via mod-
erate reduction of CDK5 expression levels. In support of
this possibility, we have previously demonstrated that
heterozygous CDK5 deficiency reverses hyperphosphory-
lation of tau in mature neurons in the frontal cortex of
gp120 tg mice [8], and that CDK5 knock-down rescues
neurogenic deficits in an animal model of AD [17]. The
present study suggests that hyperphosphorylation of
CRMP2 may be an important feature of HIV-associated
neurodegeneration, and identifies a potential link
between abnormal activation of CDK5 and impaired
neurogenesis that has been observed in animal models
of HIV neurotoxicity [36], however future studies will
be necessary to elucidate whether CRMP2 hyperpho-
sphorylation plays a direct causative role in neurogenic
or neurodegenerative alterations in the pathogenesis of
HAND.
G i v e nt h a tC R M P 2i sak n o w ns u b s t r a t eo fC D K 5 ,
along with the recent evidence that CDK5 and CRMP2
are dysregulated in HIVE [8,23,24], activation of CDK5
and subsequent hyperphosphorylation of CRMP2 may
be an important mediator of neurodegeneration in HIV
infection. The results of thep r e s e n ts t u d ya l s or e v e a la
new potential role for CRMP2 alterations in the
mechanisms of defective adult neurogenesis in neurode-
generative disorders such as HIVE. This is in line with
previous studies that have shown defective neurogenesis
in HIV patients and in animal models of HIV neurotoxi-
city (gp120 tg and others) [13,36,37].
Although the physiological function of CRMP2 has
been associated with neuronal development and neurite
outgrowth [38,39], the effects of abnormal CDK5-direc-
ted CRMP2 hyperphosphorylation in adult neurogenesis
have not been previously investigated. CRMP2 (also
known as Dpysl2) is a signaling protein that has been
s h o w nt op l a yar o l ei ng r o w t hc o n ec o l l a p s ea n da x o n
development [40]. It is a member of a group of related
proteins including CRMP1 and CRMP4, all of which are
highly abundant in the brain. CRMP2 has no known
enzymatic activity [41], however its C-terminal region is
highly Ser and Thr-rich, and is targeted for phosphory-
lation by a number of kinases, including CDK5, GSK3b
[28,42], Rho kinase [43,44], and Fyn kinase [26], among
others. Phosphorylation of CRMP2 has been reported
for at least five amino acid residues in the C-terminal
region, namely Thr509, Thr514, Ser518, Ser522 and
Thr555. Phosphorylation by CDK5 at Ser522 acts as a
priming site for subsequent phosphorylation by GSK3b
at Thr514 [25,28], while other residues can be phos-
phorylated independently of CDK5 activity. It is possible
that manipulation of phosphorylation at residues other
than Ser522 of CRMP2 might also regulate neurite out-
growth, however because CDK5 is the only kinase that
has been reported to phosphorylate the Ser522 residue,
and since phosphorylation at this site acts a gatekeeper
that regulates subsequent phosphorylation at other epi-
topes, we focused our studies on evaluating the specific
role of phosphorylation at the Ser522 residue.
In support of a pivotal role for CDK5 in the phos-
phorylation of CRMP2, a previous study demonstrated
that CRMP2 was not phosphorylated in cdk5-/- embryo-
nic brain using an antibody that recognizes several
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Page 15 of 22phosphorylated epitopes of CRMP2 (Thr509, Ser518,
and Ser522) [27]. Furthermore, the association of
CRMP2 with tubulin was enhanced in cdk5-/- brains
compared to wild-type brain, supporting the role of
CDK5-mediated phosphorylation of CRMP2 in modulat-
ing CRMP2-tubulin interactions [27]. The functional
effects of phosphorylation at the other Ser/Thr residues
of CRMP2 is not entirely clear, however previous studies
have shown that some of these post-translational modi-
fications dramatically modulate protein-protein interac-
t i o n sb e t w e e nC R M P 2a n di t sb i n d i n gp a r t n e r s ,
including tubulin heterodimers [30]. Of interest, pre-
vious studies have also shown that CDK5 and p35 can
associate with microtubules [45,46], and CDK5 sub-
strates include a number of microtubule-associated
proteins.
The results of the present study show that abnormal
activation of CDK5 and subsequent hyperphosphoryla-
tion of CRMP2 may have detrimental effects on struc-
tural elements of developing neurons, such as
microtubules and cytoskeletal organization. In support
of this possibility, we showed that the alterations in
neurite outgrowth and CRMP2 phosphorylation in p35-
overexpressing NPC-derived neural progeny were
accompanied by disrupted microtubule organization
compared to controls. Live-cell imaging of polymerized
tubulin, and ultrastructural analysis of microtubule
structure in NPC-derived neural progeny revealed dif-
fuse, mesh-like microtubule distribution under condi-
tions of p35-mediated abnormal CDK5 activation. This
was in stark contrast to more robust microtubules that
were observed under normal differentiation conditions.
Furthermore, control NPC-derived neural progeny dis-
played rapid re-polymerization of microtubules following
chemical disruption with the microtubule-destabilization
agent, nocodazole, while cultures expressing p35 showed
only minimal re-polymerization even after further incu-
bation post-washout. These observations are in line with
previous studies suggesting that the mechanisms down-
stream of abnormal CDK5 activation may involve the
destabilization of microtubules [47] and that CRMP2
plays a role in regulating microtubule dynamics [48].
Together, this supports a role for CDK5-mediated
CRMP2 hyperphosphorylation in the mechanisms of
defective adult neurogenesis in neurodegenerative condi-
tions such as HIVE.
Conclusions
Here we have shown that CRMP2 is a molecular media-
tor of abnormal CDK5 activation and impaired neuronal
maturation in an in vitro model of adult neurogenesis.
Abnormal activation of CDK5 by p35 overexpression, or
under conditions of HIV protein-mediated toxicity,
results in hyperphosphorylation of CRMP2 in an in vitro
model of adult neurogenesis. The relevance of these
results to disease mechanisms is supported by the obser-
vations of upregulated CRMP2 levels and phosphoryla-
tion in the brains of patients with HIVE and an in vivo
model of HIV-gp120 mediated neurotoxicity. The
microtubule abnormalities that accompanied CDK5 acti-
vation and CRMP2 hyperphosphorylation in the in vitro
model support the possibility that alterations in p35/
CDK5/CRMP2 signaling contribute to impaired neuro-
genesis by disturbing microtubule integrity in maturing
neurons. Targeting the CDK5/CRMP2 pathway for ther-
apeutic intervention might provide new approaches to
ameliorate the neurogenic alterations associated with
neurodegenerative conditions including HIVE.
Methods
Neuronal progenitor cell and primary neuronal cell
culture and in vitro modeling of abnormal CDK5
activation in progenitor cell and mature neuron
populations
Adult rat hippocampal (ARH) NPCs (Millipore, Teme-
cula, CA) were cultured routinely for expansion essen-
tially as previously described [49] with some
modifications. Briefly, cells were grown for expansion in
DMEM/F12 media (Mediatech, Manassas, VA) contain-
ing B27 supplement, 1X L-glutamine and 1X antibiotic-
antimycotic (all from Invitrogen, Carlsbad, CA). For
induction of neuronal differentiation, cells were plated
onto poly-ornithine/laminin (Sigma-Aldrich, St. Louis,
MO) coated plates or coverslips and transferred the
next day to differentiation media containing N2 supple-
ment (Invitrogen), 1 μM all-trans retinoic acid (Sigma-
Aldrich), 5 μM forskolin (Sigma-Aldrich) and 1% FBS.
Cells were differentiated for four days, and fresh differ-
entiation media was added at day 2. It should be noted
that this differentiation procedure generates heteroge-
neous cultures, and therefore we refer to the cells
derived from the differentiation process as “NPC-derived
neural progeny.”
To induce CDK5/p35 activity in vitro, cells were
infected on day 2 of differentiation with adenovirus
expressing human p35 or GFP control (Vector Biolabs,
Philadelphia, PA) at a multiplicity of infection (MOI) of
30. Additional control experiments were performed with
cells transfected using BPfectin according to the manu-
facturer’s guidelines (Biopioneer, San Diego, CA) with a
plasmid expressing myc-tagged p35 (Addgene plasmid
1347, deposited by Dr. Li-Huei Tsai, Picower Institute,
Cambridge, MA). Two days after infection or transfec-
tion with p35, cells were processed for immunoblot ana-
lysis with total cell lysates or immunocytochemical
analysis with fixed cells on coverslips.
Similar experiments were performed in rat hippocam-
pal primary neurons (ScienCell Research Laboratories,
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glass coverslips according to the supplier’s recommenda-
tions in Neuronal Medium (ScienCell). For induction of
CDK5/p35 activity, cells were infected two days after
plating with p35-adv at an MOI of 100. A higher MOI
was selected for the primary neuronal experiments
because these cells were plated at a lower density than
NPCs in culture. Two days after infection, cells were
prepared for immunoblot or immunocytochemical ana-
lyses. A subset of experiments were performed with
NPCs and primary hippocampal neurons where unin-
fected cells or cells infected p35-adv were exposed to
recombinant gp120 protein for 24-48 hrs (100-200 ng/
mL, LAV IIIB, Protein Sciences Corp., Meriden, CT) to
model HIV protein associated neurotoxicity in vitro.A t
the conclusion of the in vitro experiments, cells were
lysed for immunoblot analysis, or cells on coverslips
were fixed in 4% paraformaldehyde (PFA) in phosphate-
buffered saline (PBS) for immunocytochemical analysis.
Site-directed mutagenesis and generation of hCRMP2
mutant constructs
The wild-type hCRMP2/pCMV6-XL4 plasmid DNA
(Origene, Rockville, MD) was maintained in E. coli
TOP10 cells (dam
+/dcm
+ strain). Using plasmid DNA
isolated from the E. coli strain as a template, site-direc-
ted mutagenesis of hCRMP2 was carried out using a
QuickChange
® Lightning Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA) with the primers 5’-ctcggccaa-
gacggctcctgccaagcag-3’ (sense) and 5’-ctgcttggcag-
gagccgtcttggccgag-3’ (antisense) for S522A single point
mutation. The PCR reaction was performed according
to the manufacturer’s instructions, with 10-min exten-
sion cycles at 68°C. In order to remove the parental
DNA template, PCR products were subjected to DpnI
restriction enzyme digestion reaction and then directly
transformed into E. coli TOP10 cells. After selection on
LB medium supplemented with ampicillin, plasmid
DNA was extracted from positive transformants using a
QIAprep Spin Miniprep kit (Qiagen) according to the
manufacturer’s instructions. Purified plasmids were sub-
jected to DNA sequencing with hCRMP2 specific pri-
mers: 5’-atcaaggcaaggagcaggct-3’ (sense), and 5’-
aatgttgtcatcaatctgagcacca-3’ (antisense). After sequence
confirmation, the pCMV6-XL4 vector constructs con-
taining either the wild-type hCRMP2, or the S522A con-
struct were used for transformation and amplification in
XL10 E. coli cells (Stratagene).
Cell culture treatments–Pharmacological treatments, and
siRNA and CRMP2 plasmid DNA transfection
For inhibition of CDK5 activity, cells were treated at day
2 of differentiation with either the pharmacological
CDK5 inhibitor Roscovitine (1-10 μM, Calbiochem, San
Diego, CA) or transfected with siRNA against CDK5,
CRMP2, or control non-targeting fluorescent-tagged
siRNA (37.5-150 ng, 5 nM final concentration, Qiagen,
Valencia, CA) using the HiPerfect transfection reagent
(Qiagen) according to the manufacturer’s protocol. For
each target, at least two different siRNAs were tested,
and the one with the highest efficacy was selected for
subsequent experiments.
For overexpression of wild-type or mutant human (h)
CRMP2 in NPCs, cells were differentiated from day 0 in
medium without antibiotics, and transfected on day 2 of
differentiation (6 hrs prior to virus infection) with
pCMV6-XL4 plasmids hCRMP2-WT, or hCRMP2-
S522A, or pCMV-GFP control. Transfection was per-
formed using Lipofectamine 2000 transfection reagent
(Invitrogen) at a concentration of 2.5 μL/mL according
to the manufacturer’s instructions. For transfection of
cells in 6-well plates, 4.0 μg plasmid DNA was applied
per well, and for transfection of cells on coverslips in 6
cm dishes, 8.0 μg plasmid DNA was applied per dish.
Six hrs after transfection, fresh differentiation medium
without antibiotics was applied with or without viral
vectors. Cells were then lysed for biochemical analyses
or fixed for immunocytochemical analysis. For disrup-
tion of microtubules, cells were treated with nocodazole
(5 μg/mL, Sigma-Aldrich) for 3 hrs. Then, cultures were
washed with differentiation media three times, followed
by incubation in fresh media for 10 mins, 20 mins or 30
mins. Cells were then fixed with glutaraldehyde for
tubulin immunofluorescence and neurite outgrowth
analysis.
Neurite outgrowth studies
A subset of cultured cells on coverslips were fixed in a
solution containing glutaraldehyde, which better pre-
serves the cytoskeleton for optimal visualization of neur-
ites using immunofluorescence with an antibody against
b-Tubulin. For this purpose, a fixation procedure was
used essentially as previously described by Desai and
Mitchison [50]. Briefly, media was gently aspirated from
cells growing on glass coverslips, and then cells were
extracted for 30 sec in cytoskeletal buffer (CB, 80 mM
PIPES pH 6.8, 1 mM MgCl2, 4 mM EGTA) containing
0.5% freshly added Triton-X 100. Glutaraldehyde (Elec-
tron Microscopy Sciences, Hatfield, PA) was immedi-
ately added to the CB on the coverslips at a final
concentration of 0.5%. Coverslips were incubated for 10
min at 37°C. Fixative was then removed and a freshly-
prepared solution of 0.1% NaBH4 in PBS was added and
samples were incubated for 7 min at room temperature
to quench free glutaraldehyde. Coverslips were washed
at least 3 times in PBS to remove the NaBH4,a n ds a m -
ples were then processed for b-Tubulin immunofluores-
cence analysis.
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growth studies, NPC-derived neural progeny growing on
coverslips were fixed with glutaraldehyde and incubated
with a mouse monoclonal primary anti-b-Tubulin anti-
body (1:250, Clone B2.1, Sigma-Aldrich) for 1 hr at
room temperature and detected with FITC-conjugated
secondary antibodies (1:75, Vector Laboratories). b-
Tubulin-labeled coverslips were mounted under glass
coverslips with ProLong Gold antifade reagent with
DAPI (Invitrogen) and imaged with a fluorescent digital
microscopy (Olympus). For analysis of neurite out-
growth of NPC-derived neural progeny immunolabeled
with b-Tubulin, neurites were traced and lengths were
measured using the ImageJ Program (NIH, Bethesda,
MD) with the NeuronJ Plugin [51].
Live-cell staining and imaging of polymerized tubulin in
NPC-derived neural progeny
For staining of polymerized tubulin in live cells, NPC-
derived neural progeny treated with vehicle control or
p35-adv were grown on glass coverslips in 12-well plates
as described above, and incubated with Tubulin Tracker
Green (Invitrogen) according to the manufacturer’s
guidelines. Briefly, at day 4 of differentiation, media was
removed from the cultures, and replaced with 1 mL of
warm HBSS (containing Ca, Mg, and 4 mM HEPES buf-
fer [HBSS/HEPES buffer]) with 150 nM Tubulin Tracker
reagent. Plates were incubated for an additional 10 mins
at 37°C, and then washed three times in warm HBSS/
HEPES buffer. Coverslips were rapidly transferred to
slides and imaged within 5 mins on a digital fluorescent
Olympus microscope.
Electron microscopy analysis
Briefly, as previously described [52], NPCs were plated
in 35 mm dishes with a coverslip in the bottom (Mat-
Tek, Ashland, MA) and infected with p35-adv as
described in the cell culture conditions. After 4 days of
differentiation, cells were fixed in 1% glutaraldehyde in
media, then fixed in osmium tetraoxide and embedded
in epon araldite. Once the resin hardened, blocks with
the cells were detached from the coverslips and
mounted for sectioning with an ultramicrotome (Leica,
Germany). Grids were analyzed with a Zeiss OM 10
electron microscope as previously described [53].
HIV cases and neuropathological assessment
For the present study HIV+ cases with and without
encephalitis were selected from a cohort of 43 HIV+
subjects from the HIV Neurobehavioral Research Center
(HNRC) and California NeuroAIDS Tissue Network
(CNTN) at the University of California, San Diego. Sub-
jects were excluded in these analyses if they had a his-
tory of CNS opportunistic infections or non-HIV-related
developmental, neurologic, psychiatric, or metabolic
conditions that might affect CNS functioning (e.g., loss
of consciousness exceeding 30 minutes, psychosis, sub-
stance dependence). A total of 16 age-matched cases
were identified with and without encephalitis (n = 8 per
group), and without other complications, for inclusion
in the present study (Table 2). All cases had neuromedi-
cal and neuropsychological examinations within a med-
ian of 12 months before death. Most patients died as a
result of acute bronchopneumonia or septicemia, and
autopsy was performed within 24 hrs of death (Table 2).
Autopsy findings were consistent with AIDS, and the
associated pathology was most frequently due to sys-
temic CMV, Kaposi sarcoma, and liver disease. In all
cases, neuropathological assessment was performed in
paraffin sections from the frontal, parietal, and temporal
cortices, and the hippocampus, basal ganglia and brain-
stem stained with H&E, or immunolabeled with antibo-
dies against p24 and glial fibrillary acidic protein (GFAP,
marker of astrogliosis) [54,55]. The diagnosis of HIVE
was based on the presence of microglial nodules, astro-
gliosis, HIV-p24 positive cells, and myelin pallor. Forma-
lin-fixed sections and frozen brain samples were
obtained from the hippocampus of HIV and HIVE cases
for biochemical analysis. Brain tissue from HIV-infected
subjects without evidence of neuroinflammation pro-
vides a close control for the systemic effects of HIV
infection in the absence of neurodegenerative changes,
and previous studies have shown that the CDK5 path-
way is dysregulated specifically in cases with encephalitis
compared to HIV-infected non-encephalitis cases [8,56].
For these reasons, and due to the scarcity of tissue sam-
ples available from age-matched non-HIV infected con-
trol subjects, HIV-positive cases without
neuroinflammatory changes were used for comparison
with cases with HIVE.
Generation of GFAP-gp120 tg mice and crosses with
CDK5-deficient mice
For studies of CDK5 activation in an animal model of
HIV-protein mediated neurotoxicity, tg mice expressing
high levels of gp120 under the control of the GFAP pro-
moter were used [57]. These mice develop neurodegen-
eration accompanied by astrogliosis, microgliosis [57],
and memory deficits in the water maze [58]. To study
the effects of genetic CDK5 inhibition on CRMP2
expression and phosphorylation in vivo, CDK5 heterozy-
gous-deficient mice (CDK5
+/-)[ 5 9 ]w e r ec r o s s e dw i t h
the GFAP-gp120 tg mice as previously described [8].
Full ablation of both copies of CDK5 (CDK5
-/-) causes
severe neurodevelopmental alterations, so in order to
study CDK5 knockdown in the adult mouse brain, the
CDK5
+/- animals were used as a model of reduced
CDK5 activity. For in vivo studies, brain sections from
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+/-, gp120 tg, or gp120 tg/
CDK5
+/- crossed mice (n = 4 mice per group) were used
for biochemical analysis of CRMP2 expression and
phosphorylation.
Tissue processing
In accordance with NIH guidelines for the humane
treatment of animals, mice were anesthetized with
chloral hydrate and flush-perfused transcardially with
0.9% saline. Brains were removed and divided sagittally.
One hemibrain was post-fixed in phosphate-buffered 4%
paraformaldehyde at 4°C for 48 hrs and sectioned at 40
μm with a Vibratome 2000, while the other hemibrain
was snap frozen and stored at -70°C for protein analysis.
A l le x p e r i m e n t sd e s c r i b e dw e r ea p p r o v e db yt h ea n i m a l
subjects committee at the University of California at San
Diego (UCSD) and were performed according to NIH
recommendations for animal use.
Immunoblot analysis
For immunoblot analysis, adherent cells in culture or
mouse or human brain samples (0.1 g) were lysed in
buffer composed of 10 mM Tris-HCl (pH 7.4), 150 mM
NaCl, 5 mM EDTA (TNE) containing 1% Triton-X 100,
homogenized using a microgrinder, and centrifuged at
10,000 rpm for 10 minutes to clear insoluble material.
The supernatant was harvested, and protein content in
the total cell lysates was determined using the bicincho-
ninic acid protein assay kit (Pierce, Rockford, IL). Then,
20 μg of each sample was separated by gel electrophor-
esis on 4-12% Bis-Tris gels (Invitrogen) and blotted
onto 0.45 μm PVDF membranes (Millipore, Temecula,
CA). All immunoblots were incubated in primary anti-
bodies diluted in 5% BSA in PBS-Tween (PBS-T) over-
night at 4°C. Immunoblots were probed with rabbit
polyclonal antibodies against phosphorylated (pSer522)
CRMP2 (1:1000, ECM Biosciences, Versailles, KY),
phosphorylated (pThr514) CRMP2 (1:1000, Cell Signal-
ing Technology, Danvers, MA), phosphorylated
(pThr555) CRMP2 (1:1000, ECM Biosciences), total
CRMP2 (1:1000, Millipore), p35/p25 (1:500, C-19, San-
t a C r u zB i o t e c h n o l o g y ,S a n t aC r u z ,C A ) ,C D K 5( 1 : 5 0 0 ,
C-8, SantaCruz Biotechnology), or GFP (1:1000, Milli-
pore); or mouse monoclonal antibodies against b-III
Tubulin (1:5000, clone Tuj1, Covance), b-Tubulin
(1:1000, clone B2.1, Sigma-Aldrich), or GFAP (1:1000,
Millipore).
For immunoblot analysis with a panel of additional
phosphorylated or total CRMP proteins, blots were
probed with antibodies described in Table 1 at a dilu-
tion of 1:1000 for all antibodies. All immunoblots were
stripped and probed with an antibody against actin (C4
clone, Millipore) as a loading control as previously
described [53]. After incubation with primary antibodies,
blots were incubated for 45 mins at room temperature
in secondary antibodies diluted in 5% non-fat milk with
1% BSA in PBS-T. Blots were developed with enhanced
chemiluminescence (Perkin-Elmer, Waltham, MA), and
images were obtained and semi-quantitative analysis was
performed using the VersaDoc gel imaging system and
Quantity One software (Bio-Rad, Hercules, CA).
Immunocytochemistry and image analysis
For immunocytochemical analysis, briefly, as previously
described [60], cells on coverslips were fixed in 4% par-
aformaldehyde (PFA) in PBS and washed with Tris buf-
fered saline (TBS, pH 7.4). For single-label
immunostaining, coverslips were pre-treated in 3%
H2O2, blocked with 10% serum (Vector Laboratories,
Burlingame, CA), and incubated with a rabbit polyclonal
p r i m a r ya n t i b o d ya g a i n s tphospho-CRMP2 (Ser522,
1:1500, ECM Biosciences) diluted in PBS-T, and
detected with the Tyramide Signal Amplification™-
Direct (Red) system (NEN Life Sciences, Boston, MA).
Immunolabeled coverslipsw e r em o u n t e du n d e rg l a s s
coverslips with ProLong Gold antifade reagent with
DAPI (Invitrogen) and imaged with a Zeiss 63X (N.A.
1.4) objective on an Axiovert 35 microscope (Zeiss, Ger-
many) with an attached MRC1024 laser scanning confo-
cal microscope system (BioRad) [61]. All samples were
p r o c e s s e ds i m u l t a n e o u s l yu n d e rt h es a m ec o n d i t i o n s
and the experiments were performed twice to assess
reproducibility. To confirm the specificity of primary
antibodies, control experiments were performed where
sections were incubated overnight in the absence of pri-
mary antibody (deleted) or primary antibody pre-incu-
bated with blocking peptide.
For immunocytochemical analysis in human or mouse
brain tissue, briefly as previously described [61] vibra-
tome sections from the hippocampus (40 μmt h i c k )o f
the HIV patients or from nontg, gp120 tg or CDK5
+/-
mice were incubated with antibodies against phospho-
CRMP2 (Ser522, 1:300, ECM Biosciences) or CRMP2
(1:300, Millipore). Primary antibody incubation was fol-
lowed by incubation with secondary biotinylated IgG,
then avidin-HRP and diaminobenzidine (DAB) detection
as previously described [8]. Immunostained sections
were imaged with a digital Olympus microscope and
assessment of levels of immunoreactivity was performed
utilizing the Image-Pro Plus program (Media Cyber-
netics, Silver Spring, MD).
For double-labeling analysis, coverslips or brain sec-
tions were incubated with a rabbit polyclonal primary
antibody against phospho-CRMP2 (Ser522, 1:1500, ECM
Biosciences) or CRMP2 (1:1500, Millipore) detected
with Tyramide Red. The next day samples were co-
labeled with mouse monoclonal antibodies against b-III
Tubulin (1:250, Tuj1 clone, Covance) or MAP2 (1:100,
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immature neuronal marker DCX (1:100, Santa Cruz Bio-
technology), detected with FITC-conjugated secondary
antibodies (1:75, Vector Laboratories). Samples were
mounted and imaged as described above for single-
labeling immunofluorescence analysis. For each sample
a total of three sections (10 digital images per section at
400×) were analyzed in order to estimate the average
number of immunolabeled cells per unit area (mm
2)
and the average intensity of the immunostaining (cor-
rected optical density).
Statistical Analysis
All experiments were performed blind coded and in tri-
plicate. Values in the figures are expressed as means ±
SEM. To determine the statistical significance, values
were compared by unpaired two-tailed Student’st - t e s t
or by one-way ANOVA with post-hoc Dunnett’st e s t
when comparing differences to controls, or by one-way
ANOVA with post-hoc Tukey-Kramer test when com-
parisons were made among groups. The differences
were considered to be significant if p values were less
than 0.05.
Additional material
Additional file 1: Supplementary Figures 1-3 and legends. Three
supplementary figures and the corresponding figure legends are
provided as additional materials with the main manuscript submission.
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